AJOVY IS THE ONLY PREVENTIVE ANTI-CGRP
INJECTION THAT OFFERS QUARTERLY AND MONTHLY DOSING^1-5

Quarterly dosing offers long-lasting protection against migraine for
3 months at a time with no evidence of “wearing off”¹*

PATIENTS WHO TAKE
QUARTERLY DOSING ARE

~1.6x MORE ADHERENT

THAN

PATIENTS WHO TAKE
MONTHLY DOSING
OVER 12 MONTHS^6†

^† Analysis based on prescription data with patient starting months June 2022 – August 2023 and with refills tracked for 12 months (through July 2024).⁶

Patients experience similar safety and sustained efficacy, with no evidence of “wearing off,” regardless of quarterly or monthly dosing.¹

With quarterly dosing, your patients can experience fewer injection days per year ¹

Patients can start with quarterly dosing or transition to it following monthly dosing¹

QUARTERLY

AJOVY 225 mg/1.5 mL autoinjector

Sig: 675 mg subcutaneous (3 autoinjector)
every 3 months

Disp: 4.5 mL

Refills: 3

MONTHLY

AJOVY 225 mg/1.5 mL autoinjector

Sig: 225 mg subcutaneous (1 autoinjector)
every month

Disp: 1.5 mL

Refills: 11

To prescribe quarterly dosing for your patients, remember to choose 675 mg¹

No loading dose

No titration needed

Not made with natural rubber latex

Available in a prefilled syringe

Administered at home by the patient or caregiver or in office by a healthcare professional

Studied alone and in combination with oral preventive treatments

Contraindications: AJOVY® is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. Cases of anaphylaxis and angioedema have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

Adverse Reactions: The most common adverse reactions in clinical trials (≥5% and greater than placebo) were injection site reactions.

AJOVY is indicated for the preventive treatment of migraine in adults.

Please see full Prescribing Information for AJOVY.

*“Long-acting” and “lasting protection” defined as reduction in monthly average migraine or headache days measured over a 12-week period following a monthly 225 mg SC dose or quarterly 675 (225 mg x 3) SC dose.¹

CGRP: calcitonin gene-related peptide; SC: subcutaneous.

References: 1. AJOVY® (fremanezumab-vfrm) injection Current Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc. 2. Aimovig® (erenumab-aooe) injection. Prescribing Information. Thousand Oaks, CA: Amgen Inc. 3. Nurtec® ODT (rimegepant) orally disintegrating tablets. Prescribing Information. New York, NY. Pfizer Inc. 4. QULIPTA® (atogepant) tablets. Prescribing Information. North Chicago, IL. AbbVie Inc. 5. Emgality® (galcanezumab-gnlm) injection. Prescribing Information. Indianapolis, IN. Lilly USA, LLC. 6. Data on file. Parsippany, NJ: Teva Pharmaceuticals USA, Inc.

AJOVY IS THE ONLY PREVENTIVE ANTI-CGRP INJECTION THAT OFFERS QUARTERLY AND MONTHLY DOSING1-5

AJOVY IS THE ONLY PREVENTIVE ANTI-CGRP
INJECTION THAT OFFERS QUARTERLY AND MONTHLY DOSING^1-5